• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotic Polypharmacy: Helpful or Harmful?

Antipsychotic Polypharmacy: Helpful or Harmful?

January 1, 2016
Kelly N. Gable, Pharm.D and Daniel Carlat, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Kelly N. Gable, Pharm.D Associate Professor, SIUE School of Pharmacy Psychiatric Care Provider, Places for People Dr. Gable has disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.   Daniel Carlat, MD Editor-in-Chief, Publisher, The Carlat Report. Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Prescribing two antipsychotics to a single patient is a common practice in clinical settings. One study estimated that up to 50% of psychiatric inpatients are receiving antipsychotic polypharmacy (Faries D et al, BMC Psychiatry;5:26). Increasingly, we are being scolded for this practice. A variety of guidelines discourage polypharmacy, and recent studies have documented that we are often not following such guidelines.

Clearly, psychiatrists aren’t combining drugs in order to be obstinate, to cost the system more money, or to harm patients. We’re doing it because we want to make our patients feel better, and in many cases a single drug is not doing the trick. Studies indicate that the patients who are more likely to be prescribed multiple antipsychotics are younger, single, unemployed, and male; they also present with more severe psychotic symptoms. Patients with frequent hospital admissions, involuntary admissions, and those prescribed long-acting injectables (LAI) are also more likely to eventually be on two antipsychotics at the same time (Fleischhacker WW and Uchida H, Int J Neuropsychopharmacol 2014;17(7):1083–1093).

If possible, stick with a single antipsychotic. But if the situation seems to call for polypharmacy, here are some factors to guide your decision-making. The published evidence base for any combination regimen is either slim or non-existent, so consider these to be commonsense guidelines drawn from clinical experience (when there are actual studies endorsing these practices, we cite them below).

Consider the differing receptor-binding profiles of the many antipsychotics available for use (see table below). First-generation antipsychotics, such as Haldol, bind tightly to dopamine receptors and occupy the sites longer. Some second-generation antipsychotics, especially quetiapine and clozapine, are known to have a quick “on-off” effect, meaning they dissociate from the dopamine receptor quickly (McIntosh DM et al, The Canadian Journal of Diagnosis 2011; (4):33–44). How does receptor affinity translate to clinical practice? Generally, longer and tighter binding to D2 will trigger more extrapyramidal side effects (EPS), whereas quick on-off binding translates to minimal or no risk of EPS development. Also take note of other receptor binding activity, such as histamine, alpha, and muscarinic, all of which are described in the table. Using this information, for example, you would predict that two highly histaminergic or muscarinic blocking antipsychotics, like clozapine and olanzapine, will likely lead to a very tired, cognitively impaired, and constipated patient.
Table: Antipsychotic Receptor Binding Affinities

Table: Antipsychotic Receptor Binding Affinities

Click here to view full-size PDF.

 

Some common polypharmacy scenarios
Our clinical experience indicates that there are a few common scenarios leading to multiple antipsychotics. We’ll describe each in turn, and comment on which ones are more or less reasonable.

1) Attempting to gain more rapid control of psychotic symptoms
Current treatment: quetiapine or other low-potency agent. Potential addition: haloperidol 1–2 mg every 6 hours PRN agitation, po or IM, depending on situation and setting.
This scenario is often appropriate. Haloperidol can be used to control acute agitation on top of an atypical antipsychotic, and it frequently works. One could also use other higher-potency antipsychotics, such as aripiprazole, risperidone, or paliperidone. Overall, we suggest limiting such combinations to short term use (1–4 weeks). Too many antipsychotics with complicated dosing schedules will only lead to difficulty with treatment adherence.

2) Refractory cases
Current treatment: clozapine. Potential addition: risperidone 1 mg daily due to poor symptom control: low-potency oral agent.
Clozapine is the clear favorite when it comes to the treatment of refractory schizophrenia. But what do we do when clozapine isn’t enough? Adding risperidone to clozapine has become a favorite of clinicians, based on two placebo-controlled trials (Freudenreich O et al, J Clin Psychiatry 2009;70(12):1674–1680 and Josiassen RC et al, Am J Psychiatry 2005;162(1):130–136), though one larger trial showed no beneficial effect of adding risperidone (Honer et al, N Engl J Med 2006;354(5):472–482). We suggest trying this option only after a solid 12-week trial of clozapine monotherapy at therapeutic doses of 300–900 mg daily.

3) Management of acute symptom exacerbations during treatment with an LAI antipsychotic
Current treatment: paliperidone LAI IM q 4 weeks, or other LAI. Potential addition: low-potency oral agent.

Your patient has a worsening of psychosis, despite taking the maximum recommended dose of an LAI. There is no evidence-based guidance on to how to approach this problem. You will probably be reluctant to discontinue the shot if your patient has responded well to it in the past. You could consider shortening the interval of the injection first (eg, move from every 4 weeks to every 3 weeks). When you do add on a second antipsychotic, try one with a differing receptor-binding profile (see table). Be mindful of worsening EPS and hyperprolactinemia with these combinations. Ensure that you reevaluate the regimen routinely, and attempt to remove the additional oral antipsychotic periodically.

4) Treatment of co-occurring insomnia 
Current treatment: risperidone. Potential addition: quetiapine 50 mg q HS.
It is quite common for psychiatrists to prescribe quetiapine for insomnia, agitation, and anxiety (Philip NS et al, Ann Clin Psychiatry 2008;20(1):15–20). A survey of Medicaid prescribing from 2004 indicated that quetiapine was the most likely antipsychotic to be co-prescribed long-term with other antipsychotics (Ganguly et al, J Clin Psychiatry 2004;65(10):1377–1388). Once you have maxed out your dopamine blocking threshold (for Haldol or Prolixin, this is between 10 and 20 mg a day), it does make sense to consider the addition of a low-potency, sedating antipsychotic—if the problem being targeted is psychosis. For a patient with insomnia, consider a sleep study referral, or a trial with one of the many dedicated hypnotics, such as benzodiazepines, non-benzos, melatonin, and others. Our suggestion would be to avoid antipsychotic polypharmacy here if you can. Quetiapine, while sedating and calming, is also likely to cause or exacerbate troublesome metabolic side effects such as weight gain and diabetes.

5) Treatment of antipsychotic-induced adverse effects
Current treatment: risperidone. Potential addition: aripiprazole to lower prolactin levels induced by risperidone.

There are varying opinions on the appropriateness of using an antipsychotic to treat antipsychotic-induced side effects. There are several studies highlighting the effectiveness of aripiprazole at reducing prolactin levels induced by other antipsychotics (Kane JM et al, J Clin Psychiatry 2009;70(10):1348–1355). This is due to its dopamine agonist properties. The biggest concern with this combination is the financial burden associated with its use, though aripiprazole will become much cheaper with time now that it is available as a generic. This combination should be considered for patients who have had a positive response to risperidone therapy but have significant hyperprolactinemia.

There are also limited data describing the benefit of adding aripiprazole to clozapine therapy to reduce metabolic-associated adverse effects. Adding aripiprazole to clozapine (Fan et al, 2013) or olanzapine (Henderson et al, J Clin Psychopharmacol 2009;29(2);165–169) has resulted in weight loss and LDL cholesterol lowering; however, you may not see a robust change in psychosis (Kane JM et al, J Clin Psychiatry 2009;70(10):1348–1355).

6) Caught in the cross-taper/titration
Current treatment: lurasidone (tapering due to poor response). Potential addition: olanzapine, with plan to titrate up while tapering lurasidone, but patient has a positive response to both treatments together.

Even great clinicians can be a victim of the taper/titration trap. All you really know here is that lurasidone didn’t cut it by itself, and when you added olanzapine, the patient got better. So, was it the olanzapine or was it the combo? Sometimes it is just easier to leave well enough alone and not risk symptom relapse. Despite this, your patient deserves a try with olanzapine solo before keeping the combination going long-term. There are just no good data to support this kind of duo, and again, the risk of side effects continues to grow. An adequate taper/titration schedule should really be done within 8 weeks.

TCPR Verdict: Combining antipsychotics can be helpful in some situations, but monitor closely for side effects and try to reduce back to monotherapy if possible.
General Psychiatry
KEYWORDS antipsychotics bipolar_disorder
    Kelly N. Gable, Pharm.D

    More from this author
    Carlat 150x150
    Daniel Carlat, MD

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2016
    SUBSCRIBE NOW
    Table Of Contents
    Managing Bipolar Disorder: Practical Tips
    Antipsychotic Polypharmacy: Helpful or Harmful?
    ICD-10: What You Need to Know
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.